Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

Elizaga ML, Li SS, Kochar NK, Wilson GJ, Allen MA, Tieu HVN, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, Latham TE, Clarke DK, Egan MA, Eldridge JH, Hannaman D, Xu R, Ota-Setlik A, McElrath MJ, Hay CM; NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team.

PLoS One. 2018 Sep 20;13(9):e0202753. doi: 10.1371/journal.pone.0202753. eCollection 2018.

2.

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.

Suksanpaisan L, Xu R, Tesfay MZ, Bomidi C, Hamm S, Vandergaast R, Jenks N, Steele MB, Ota-Setlik A, Akhtar H, Luckay A, Nowak R, Peng KW, Eldridge JH, Clarke DK, Russell SJ, Diaz RM.

Mol Ther Oncolytics. 2018 Jul 5;10:1-13. doi: 10.1016/j.omto.2018.05.001. eCollection 2018 Sep 28.

3.

Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.

Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL Jr, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, Eldridge JH.

J Virol. 2017 Nov 15. pii: JVI.01190-17. doi: 10.1128/JVI.01190-17. [Epub ahead of print]

4.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

5.

Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Nasar F, Matassov D, Seymour RL, Latham T, Gorchakov RV, Nowak RM, Leal G, Hamm S, Eldridge JH, Tesh RB, Clarke DK, Weaver SC.

J Virol. 2017 Mar 29;91(8). pii: e01729-16. doi: 10.1128/JVI.01729-16. Print 2017 Apr 15.

6.

Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, Kochhar S, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group.

Vaccine. 2016 Dec 12;34(51):6597-6609. doi: 10.1016/j.vaccine.2016.06.071. Epub 2016 Jul 6. Review.

7.

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).

Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, Sheets R, Pensiero M, Tremblay MA, Higgins TJ, Latham T, Egan MA, Clarke DK, Eldridge JH; HVTN 090 Study Group and the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network, Mulligan M, Rouphael N, Estep S, Rybczyk K, Dunbar D, Buchbinder S, Wagner T, Isbell R, Chinnell V, Bae J, Escamilla G, Tseng J, Fair R, Ramirez S, Broder G, Briesemeister L, Ferrara A.

Open Forum Infect Dis. 2015 Jun 5;2(3):ofv082. doi: 10.1093/ofid/ofv082. eCollection 2015 Sep.

8.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.

9.

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.

Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW.

Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.

10.

Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.

Clarke DK, Nasar F, Chong S, Johnson JE, Coleman JW, Lee M, Witko SE, Kotash CS, Abdullah R, Megati S, Luckay A, Nowak B, Lackner A, Price RE, Little P, Kalyan N, Randolf V, Javadian A, Zamb TJ, Parks CL, Egan MA, Eldridge J, Hendry M, Udem SA.

J Virol. 2014 Jun;88(12):6690-701. doi: 10.1128/JVI.03441-13. Epub 2014 Apr 2.

11.

Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Xu R, Nasar F, Megati S, Luckay A, Lee M, Udem SA, Eldridge JH, Egan MA, Emini E, Clarke DK.

J Virol. 2009 Oct;83(19):9813-23. doi: 10.1128/JVI.00550-09. Epub 2009 Jul 22.

12.

In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.

Johnson JE, Coleman JW, Kalyan NK, Calderon P, Wright KJ, Obregon J, Ogin-Wilson E, Natuk RJ, Clarke DK, Udem SA, Cooper D, Hendry RM.

Vaccine. 2009 May 14;27(22):2930-9. doi: 10.1016/j.vaccine.2009.03.006. Epub 2009 Mar 13.

13.

Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.

Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, Johnson JE, Coleman JW, Lee M, Kotash C, Yurgelonis I, Natuk RJ, Hendry RM, Udem SA, Clarke DK.

J Virol. 2008 Jan;82(1):207-19. Epub 2007 Oct 17.

14.

Simultaneous quantification of four RNA targets by multiplex, real-time RT-PCR without optimization.

Coleman JW, Johnson JE, Clarke DK.

Biotechniques. 2007 Sep;43(3):369-71. No abstract available.

15.

Quantitative multiplex assay for simultaneous detection of the Indiana serotype of vesicular stomatitis virus and HIV gag.

Coleman JW, Ogin-Wilson E, Johnson JE, Nasar F, Zamb TP, Clarke DK, Hendry RM, Udem SA.

J Virol Methods. 2007 Jul;143(1):55-64. Epub 2007 Mar 26.

PMID:
17382412
16.

Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations.

Clarke DK, Nasar F, Lee M, Johnson JE, Wright K, Calderon P, Guo M, Natuk R, Cooper D, Hendry RM, Udem SA.

J Virol. 2007 Feb;81(4):2056-64. Epub 2006 Dec 6.

17.

Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates.

Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, Draper K, Lee M, Reilly PA, Clarke DK, Hendry RM, Udem SA.

Virology. 2007 Mar 30;360(1):36-49. Epub 2006 Nov 13.

18.

Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.

Clarke DK, Cooper D, Egan MA, Hendry RM, Parks CL, Udem SA.

Springer Semin Immunopathol. 2006 Nov;28(3):239-53. Epub 2006 Sep 15. Review.

PMID:
16977404
19.

Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.

Natuk RJ, Cooper D, Guo M, Calderon P, Wright KJ, Nasar F, Witko S, Pawlyk D, Lee M, DeStefano J, Tummolo D, Abramovitz AS, Gangolli S, Kalyan N, Clarke DK, Hendry RM, Eldridge JH, Udem SA, Kowalski J.

J Virol. 2006 May;80(9):4447-57.

20.

An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development.

Witko SE, Kotash CS, Nowak RM, Johnson JE, Boutilier LA, Melville KJ, Heron SG, Clarke DK, Abramovitz AS, Hendry RM, Sidhu MS, Udem SA, Parks CL.

J Virol Methods. 2006 Jul;135(1):91-101. Epub 2006 Mar 29.

PMID:
16569439
21.

Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.

Egan MA, Chong SY, Rose NF, Megati S, Lopez KJ, Schadeck EB, Johnson JE, Masood A, Piacente P, Druilhet RE, Barras PW, Hasselschwert DL, Reilly P, Mishkin EM, Montefiori DC, Lewis MG, Clarke DK, Hendry RM, Marx PA, Eldridge JH, Udem SA, Israel ZR, Rose JK.

AIDS Res Hum Retroviruses. 2004 Sep;20(9):989-1004.

PMID:
15585086
22.

Rescue of mumps virus from cDNA.

Clarke DK, Sidhu MS, Johnson JE, Udem SA.

J Virol. 2000 May;74(10):4831-8.

23.

Evolution of fitness in experimental populations of vesicular stomatitis virus.

Elena SF, González-Candelas F, Novella IS, Duarte EA, Clarke DK, Domingo E, Holland JJ, Moya A.

Genetics. 1996 Mar;142(3):673-9.

24.

Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells.

Novella IS, Clarke DK, Quer J, Duarte EA, Lee CH, Weaver SC, Elena SF, Moya A, Domingo E, Holland JJ.

J Virol. 1995 Nov;69(11):6805-9.

25.

A comparison of the nucleotide sequences of eastern and western equine encephalomyelitis viruses with those of other alphaviruses and related RNA viruses.

Weaver SC, Hagenbaugh A, Bellew LA, Netesov SV, Volchkov VE, Chang GJ, Clarke DK, Gousset L, Scott TW, Trent DW, et al.

Virology. 1994 Aug 1;202(2):1083. No abstract available.

PMID:
8030217
26.

RNA virus quasispecies: significance for viral disease and epidemiology.

Duarte EA, Novella IS, Weaver SC, Domingo E, Wain-Hobson S, Clarke DK, Moya A, Elena SF, de la Torre JC, Holland JJ.

Infect Agents Dis. 1994 Aug;3(4):201-14. Review.

PMID:
7827789
27.

Subclonal components of consensus fitness in an RNA virus clone.

Duarte EA, Novella IS, Ledesma S, Clarke DK, Moya A, Elena SF, Domingo E, Holland JJ.

J Virol. 1994 Jul;68(7):4295-301.

28.

The red queen reigns in the kingdom of RNA viruses.

Clarke DK, Duarte EA, Elena SF, Moya A, Domingo E, Holland J.

Proc Natl Acad Sci U S A. 1994 May 24;91(11):4821-4.

29.

The correction of coagulometer effects on international normalized ratios: a multicentre evaluation.

Poller L, Thomson JM, Taberner DA, Clarke DK.

Br J Haematol. 1994 Jan;86(1):112-7.

PMID:
8011518
30.

A comparison of the nucleotide sequences of eastern and western equine encephalomyelitis viruses with those of other alphaviruses and related RNA viruses.

Weaver SC, Hagenbaugh A, Bellew LA, Netesov SV, Volchkov VE, Chang GJ, Clarke DK, Gousset L, Scott TW, Trent DW, et al.

Virology. 1993 Nov;197(1):375-90. Erratum in: Virology. 1994 Aug 1;202(2):1083.

PMID:
8105605
31.

Many-trillionfold amplification of single RNA virus particles fails to overcome the Muller's ratchet effect.

Duarte EA, Clarke DK, Moya A, Elena SF, Domingo E, Holland J.

J Virol. 1993 Jun;67(6):3620-3.

32.

Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses.

Clarke DK, Duarte EA, Moya A, Elena SF, Domingo E, Holland J.

J Virol. 1993 Jan;67(1):222-8.

33.

Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses.

Holland JJ, de la Torre JC, Clarke DK, Duarte E.

J Virol. 1991 Jun;65(6):2960-7.

34.

The nucleotide sequence of the gene encoding the attachment protein H of canine distemper virus.

Curran MD, Clarke DK, Rima BK.

J Gen Virol. 1991 Feb;72 ( Pt 2):443-7.

PMID:
1993883
36.

Characterization of clones for the sixth (L) gene and a transcriptional map for morbilliviruses.

Rima BK, Baczko K, Clarke DK, Curran MD, Martin SJ, Billeter MA, ter Meulen V.

J Gen Virol. 1986 Sep;67 ( Pt 9):1971-8.

PMID:
3755751
37.

cDNA cloning of the messenger RNAs of five genes of canine distemper virus.

Russell SE, Clarke DK, Hoey EM, Rima BK, Martin SJ.

J Gen Virol. 1985 Mar;66 ( Pt 3):433-41.

PMID:
3838337

Supplemental Content

Loading ...
Support Center